Oncology

Late-breaking data from the ESMO Congress 2019 demonstrate osimertinib’s superiority to older generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer.

At ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the latest practice-changing clinical data results involving PARP inhibitor therapy in ovarian cancer.

Five-year overall survival rates in patients with melanoma were 52% for nivolumab plus ipilimumab, 44% for nivolumab, and 26% for ipilimumab.  

Research discusses specific mindsets that could affect the health of patients with cancer: regarding the disease as either a catastrophe or an opportunity and seeing the body as either a friend or foe.

Improvements in overall survival and response rates found in patients with advanced hepatocellular carcinoma treated with first-line nivolumab.

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.

The European Society for Medical Oncology (ESMO) Congress 2019 will be taking place September 27 to October 1 in Barcelona, Spain, and Pharmacy Times® and Specialty Pharmacy Times® will be on location delivering coverage.

Mammography found more effective at detecting breast cancer in men with high risk than for women with an average risk and in detecting the disease before it metastasizes.

Top news of the day across the health care landscape.

Study shows that higher levels of PTSD symptoms can be associated with increased risks of ovarian cancer even decades after women experience a traumatic event.

Cyclin-Dependent Kinase 4/6 Inhibitors, Margetuximab, Trastuzumab Deruxtecan, and Tyrosine Kinase Inhibitors Have Shown Promising Results

Obesity-associated cancer burden is shifting toward younger individuals, with more dramatic increases in some populations than others.

The FDA has approved Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC), based on the results from the Phase 3 TITAN study.

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.

Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.

During a presentation at the recent Community Oncology Alliance Annual Conference in Orlando, Florida, Ray Bailey, RPh, discussed the implications of medical marijuana for patients with cancer.

Despite advances in cancer care, patients typically face obstacles to treatment.

As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.

The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.

Study finds association between obesity and a greater burden of symptoms and distress among patients with breast or prostate cancer.

Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer.

As a nonprofit focused on enhancing patient care. COPA is in a unique position to serve as a noncommercial organization dedicated to addressing community oncology pharmacy issues, all in the sole interest of patient care.

Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

There are currently no FDA-approved targeted therapies to treat metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), according to the Novartis.

As new specialty products have begun to dominate the developmental pipeline, specialty pharmacy has entered the mainstream of the supply chain to the point where we can arguably refer to much of the channel as “traditional specialty.”

Two separate studies highlighted how high drug costs and requirements for prior authorization can hinder access to cancer treatment and affect outcomes.

Oncologists suggest that substituting nab-paclitaxel instead of paclitaxel prior to surgery may lead to reduced risk of disease recurrence for certain women with breast cancer.

Building on the current understanding of spihingosine 1-phosphate levels in regulating T cell function, researchers found that the inhibition of the lipid can lead to more effective uses of immunotherapy in cancer therapy.